mondoBIOTECH Holding AG

On 25 January 2013 mondoBIOTECH Holding AG and Pierrel SpA announced that they had entered into a binding agreement for the combination of the Contract Research Organization (CRO) of Pierrel SpA with mondoBIOTECH.

Thereby, Pierrel SpA, a global pharmaceutical provider listed on the Italian stock exchange, will contribute 100% of the share capital of PIerrel Research International AG, the holding company of the CRO, by way of a contribution in kind through a dedicated capital increase of mondoBIOTECH, a Swiss drug discovery company focused on repurposing drugs in rare and neglected diseases which is listed on the Swiss stock exchange. The business combination is subject to a number of closing conditions.

A team of Froriep Renggli, lead by Partner Marco A. Rizzi and Dr. Mark Montanari, advises mondoBIOTECH Holding AG on all Swiss law aspects of the business combination.